Study of cladribine, ruxolitinib, and venetoclax for T-PLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with T-PLL that has relapsed (come back) or is refractory (did not respond to treatment).
- You must be 18 years or older.
- You must have adequate liver and kidney function, and a heart pump function (ejection fraction) of 45% or higher within the last 3 months.
- You must be able to perform daily activities with little to no help (ECOG performance status 0-2).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study.
- You cannot have had prior treatment with a JAK inhibitor (like ruxolitinib) or have active uncontrolled infections, heart failure, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
This trial tests APG-115 alone or with APG-2575 in adults whose T-PLL or NHL has come back or did not respond to treatment. It may help by targeting the cancer cells with a new drug approach when standard therapies have not worked.
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Hear when a new T-cell Prolymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.